Lanreotide Powder Cas No.108736-35-2
Source: Synthetic
Specification: ≥99%
CAS No: 108736-35-2
Molecular Formula: C₅₄H₆₉N₁₁O₁₀S₂
Molecular Weight: 1096.3 g/mol
Analytical Method: HPLC
Active Ingredient: Lanreotide
Product Characteristics: White or off-white lyophilized powder or solid
Packaging: Available in various specifications (mg, g, kg), customizable
Storage Condition: Should be sealed, protected from light, and stored in a dry environment at -20°C or lower
Shelf Life: 24 months
Declaration of Use: This product is intended for industrial use or scientific research only.
Lanreotide API Powder
Somatostatin Analog | Pharmaceutical Grade Raw Material
⚠️ REGULATORY COMPLIANCE & RESEARCH USE ONLY (RUO): This high-purity Lanreotide is supplied strictly as a raw material API powder for professional laboratory research, biopharmaceutical formulation development, and in-vitro/in-vivo assays. It is NOT a finished pharmaceutical drug and is explicitly prohibited for direct administration to humans or animals.
🔬 Receptor Specificity
Exceptionally high binding affinity to somatostatin receptors (SSTR2 and SSTR5) for targeted neuroendocrine therapeutic R&D.
📑 Comprehensive Dossier
Complete analytical packages including absolute HPLC sequence mapping, ESI-MS, and residual solvent tracking for generic ANDA filings.
❄️ Disulfide Bridge Integrity
Maintained strictly at -20°C in desiccated, tight containers to preserve structural conformation and prevent hygroscopic degradation.
Product Characterization
Lanreotide is a highly potent, synthetic octapeptide analog of naturally occurring somatostatin. Engineered for advanced biopharmaceutical research, Xi'an Tihealth Biotechnology Co., Ltd. supplies this active pharmaceutical ingredient (API) with a rigorously validated HPLC purity of ≥ 99.0%.
Characterized by its extended in vivo half-life and exceptionally high binding affinity to somatostatin receptors (specifically SSTR2 and SSTR5), our Lanreotide API is structurally optimized for the development of advanced sustained-release (SR) depot formulations and targeted neuroendocrine therapeutics.
Chemical Profile & Specification Parameters
| Analytical Parameter | Xi'an Tihealth Specification |
|---|---|
| Generic Name | Lanreotide (Acetate) |
| CAS Registry Number | 108736-35-2 |
| Molecular Formula | C54H69N11O10S2 |
| Molecular Weight | 1096.3 g/mol |
| Peptide Purity (HPLC) | ≥ 99.0% |
| Appearance | White to off-white lyophilized powder |
Storage & Handling Protocols: Preserve in tight, light-resistant containers. Store strictly at -20°C in a desiccated environment to maintain the disulfide bridge structural integrity. Allow the sealed vial to equilibrate to room temperature before opening to prevent hygroscopic degradation.
Pharmacodynamics & Receptor Interaction
- Hormonal Secretion Suppression: High-affinity binding to SSTR2 and SSTR5 potently suppresses pathological hypersecretion of Growth Hormone (GH), IGF-1, and gastrointestinal peptides.
- Antiproliferative Cascade: Upregulates protein tyrosine phosphatases (PTPs), interfering with mitogenic signaling pathways and restricting tumor expansion.
- Anti-Angiogenic Potential: Downregulates the expression and release of vascular endothelial growth factor (VEGF).
R&D Applications
- Long-Acting Depot Formulation Research: Foundation for innovative delivery systems, including self-assembling supersaturated hydrogels (Autogel) and PLGA microsphere injections (28-day sustained release).
- Endocrinology & Oncology: Core API for generic equivalents targeting Acromegaly management and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).
- Exploratory Clinical Pathways: High-purity reference material for investigating potential indications in refractory ophthalmic pathologies.
Technical & Formulation FAQ
Is this API suitable for self-assembling nanostructure/hydrogel formulation studies?
Yes. Our Lanreotide API is engineered with highly controlled physicochemical properties, allowing it to spontaneously form stable, supersaturated liquid crystal nanotubes in aqueous environments when subjected to specific preparation protocols. This makes it ideal for developing "Autogel" style deep subcutaneous depot injections.
What is the counter-ion utilized in your Lanreotide API?
Our standard commercial API is supplied as Lanreotide Acetate. The acetate salt form provides the optimal balance of solubility and stability required for both microsphere encapsulation and high-concentration aqueous dispersion technologies.
What analytical validation is provided for generic bioequivalence (BE) studies?
To support strict generic drug development (ANDA submissions), Xi'an Tihealth provides a comprehensive analytical dossier. This includes the Certificate of Analysis (COA), absolute HPLC sequence mapping to confirm the absence of deletion/insertion impurities, Electrospray Ionization Mass Spectrometry (ESI-MS), and rigorous residual solvent tracking.
Hot Tags: lanreotide powder cas no.108736-35-2, China lanreotide powder cas no.108736-35-2 manufacturers, suppliers, factory, tranexamic powder
You Might Also Like
Send Inquiry